SpyGlass Pharma Stock
SpyGlass Pharma, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Patrick H. Mooney
- Employees
- 76
- Market cap
- $803 M
- IPO
- 06/02/2026
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard…
SpyGlass Pharma stock: price history
1D
-2.9%
1W
-3.7%
1M
-16.1%
6M
-3.8%
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~33% stronger price swings than usual
Ask the agents about SpyGlass Pharma
Analyst assessment of SpyGlass Pharma
PRICE TARGET LOW
US$37.00
CONSENSUS
US$38.00
MEDIAN
US$38.00
PRICE TARGET HIGH
US$39.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 05/10/2026
SpyGlass Pharma stock metrics
P/E
-14.46
P/B
3.45
EV/EBITDA
-9.95
RETURN ON EQUITY
-8.5%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
41.8%
FLOAT SHARES
13,967,542
AVG. DAILY VOLUME (30D)
123,816
Institutional holders
Comparable stocks
Frequently asked questions about SpyGlass Pharma stock
What does SpyGlass Pharma do?
SpyGlass Pharma, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Patrick H. Mooney, the company employs around 76 people.
The IPO was on 06/02/2026; the stock trades on NASDAQ under the ticker SGP.
What do analysts say about SpyGlass Pharma stock?
1 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$38.00, ranging from US$37.00 to US$39.00, with a median of US$38.00.
This is an external assessment, not a statement by Market Jury.
When does SpyGlass Pharma report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 33% stronger than usual.
Does SpyGlass Pharma pay a dividend?
No, SpyGlass Pharma currently does not pay a dividend.
Which stocks are comparable to SpyGlass Pharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get SpyGlass Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess SpyGlass Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.